- $15.25m
- $17.04m
Annual income statement for Biomx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.3 | 35.5 | 27.2 | 25.3 | 44.5 |
| Operating Profit | -30.3 | -35.5 | -27.2 | -25.3 | -44.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -30.1 | -36.2 | -28.3 | -26.1 | -17.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -30.1 | -36.2 | -28.3 | -26.2 | -17.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -30.1 | -36.2 | -28.3 | -26.2 | -17.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30.1 | -36.2 | -28.3 | -26.2 | -17.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13 | -1.39 | -0.949 | -0.51 | -0.943 |